Introduction: Despite recent advances in the management of HIV infection and increased access to treatment, prevention, care and support, the HIV/AIDS epidemic continues to be a major global health problem, with sub-Saharan Africa suffering by far the greatest humanitarian, demographic and socio-economic burden of the epidemic. Information on HIV/AIDS clinical care and established cohorts' characteristics in the Central Africa region are sparse. Methods: A survey of clinical care resources, management practices and patient characteristics was undertaken among 12 adult HIV care sites in four countries of the International Epidemiologic Databases to Evaluate AIDS Central Africa (IeDEA-CA) Phase 1 regional network in October 2009. These facilities served predominantly urban populations and offered primary care in the Democratic Republic of Congo (DRC; six sites), secondary care in Rwanda (two sites) and tertiary care in Cameroon (three sites) and Burundi (one site). Results: Despite some variation in facility characteristics, sites reported high levels of monitoring resources, including electronic databases, as well as linkages to prevention of mother-to-child HIV transmission programs. At the time of the survey, there were 21,599 HIV-positive adults (median age 037 years) enrolled in the clinical cohort. Though two-thirds were women, few adults (6.5%) entered HIV care through prevention of mother-to-child transmission services, whereas 55% of the cohort entered care through voluntary counselling and testing. Two-thirds of patients at sites in Cameroon and DRC were in WHO Stage III and IV at baseline, whereas nearly all patients in the Rwanda facilities with clinical stage information available were in Stage I and II. WHO criteria were used for antiretroviral therapy initiation. The most common treatment regimen was stavudine/lamivudine/ nevirapine (64%), followed by zidovudine/lamivudine/nevirapine (19%).
Introduction
Despite the recent advances in the management of HIV infection and the increased access to treatment, prevention, care and support, the HIV/AIDS epidemic continues to be a major global health problem [1] . Treatment regimens with highly active antiretroviral therapy (HAART) have transformed the infection to a manageable condition [2] , and quantifiable improvements in many indicators are evident due to the HIV/ AIDS programs internationally [3] . However, the epidemic confers disproportionate humanitarian, demographic and socio-economic impacts in certain areas of the world [4, 5] .
Sub-Saharan Africa suffers by far the greatest burden of the epidemic [4, 6] , and this poses extreme pressures in the affected countries' capacities and human resources [7] .
The scaling up of HAART [8, 9] and voluntary HIV counselling and testing (VCT) in combination with immediate antiretroviral therapy (ART) [10] , as well as care delivery and monitoring systemic improvements [11] , have shown promising results. In spite of these great steps forward, enormous and diverse challenges, such as late ART initiation and high rates of loss to follow-up, still persist [12Á14] .
In response to the ''global imperative'' created by the epidemic [15, 16] , an unprecedented array of scientific and financial resources has been mobilized, along with a global political commitment expressed in the Millennium Development Goals [17] . Long-lasting scientific initiatives [18, 19] in industrialized nations have advanced the current state of knowledge and care of those with HIV infection and AIDS.
During the last decade, increased funding allocation was made possible via major funders such as the US President's Emergency Plan for AIDS Relief (PEPFAR), The Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the World Bank. These resources provided new opportunities for HIV/AIDS prevention, treatment and care in low-resource regions [20] .
This scaling-up created an immediate need for high-quality research and implementation science to help inform the scale-up process, as well as effective planning, monitoring and evaluation of HIV/AIDS related programs, through international collaborations [21, 22] . In response, the International Epidemiologic Databases to Evaluate AIDS (IeDEA) was initiated in 2006 with funding from the US National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID) to function as a data harmonization and collaboration platform. The Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD) provides additional support to conduct paediatric research, and the National Cancer Institute (NCI) to initiate cancer-related research in Africa through the IeDEA regional centres and affiliated sites. Currently, there are seven funded IeDEA participating regions in five continents. The present paper describes the results of a survey that was undertaken among the adult HIV care facilities of the IeDEA-Central Africa (CA) Phase 1 network with the goals of summarizing, comparing and presenting information on clinical care resources, management practices and patient characteristics within the regional network.
Methods
The IeDEA-CA network The international research consortium of IeDEA (www.idea. org) has established regional centres that monitor highquality data collection, entry and storage, in a uniform or compatible manner across the seven regions: North America [23] , Latin America and Caribbean [24] , Asia/Pacific, West Africa, Central Africa, East Africa and Southern Africa. IeDEA enables researchers around the world to address novel and evolving research questions in HIV/AIDS that are currently unanswerable by single cohorts. A description of the entire IeDEA sub-Saharan Africa clinical cohort profile has been recently published [25] . From 2006 to 2011, the Phase 1 Central Africa collaboration, in particular, consisted of a total of 13 facilities providing adult HIV care and treatment (10 adult HIV care and treatment clinics from Burundi, Cameroon, and Democratic Republic of Congo (DRC) plus three adult clinics in Rwanda) and four facilities providing paediatric HIV care and treatment in Burundi, Cameroon and DRC. Countrylevel information on population characteristics and prevalence estimates of HIV infection and ART for these four countries based on the UNAIDS 2008 Report on the Global AIDS epidemic [26Á29] are presented in Table 1 .
Data were collected and entered at participating health facilities into separate paediatric and adult databases and merged at the data coordinating centre at RTI International in the United States. The collaboration built on the existing partnerships between the Kinshasa School of Public Health, RTI International, the University of North Carolina at Chapel Hill Gillings School of Global Public Health, as well as the Institute of Tropical Medicine Antwerp, Belgium. Local collaborators included the HIV/AIDS clinicians/care providers, representatives of national HIV/AIDS programs, faculty from medical schools in the region, as well as the International Center for AIDS Care and Treatment Programs (ICAP) at Columbia University that contributed data from Rwanda. For the purposes of this study, we focused on the clinics providing adult care and did not include four participating paediatric care centres, one in DRC, two in Cameroon and one in Burundi, due to differences in paediatric and adult cohort characteristics. We also excluded one site with exclusive care of female patients in Rwanda because this site differed from the other sites in the IeDEA-CA consortium in terms of the unique population that it serves (the majority are survivors of genocidal rape).
Data collection and analysis
Periodic assessments to obtain information on site resources, facilities, clinical practices, staffing, patient attendance and care, and additional services or programs offered at the site were undertaken within the IeDEA-CA collaboration. For the In terms of patient characteristics, sites in the IeDEA-CA network collected standardized baseline data for each participant, as well as follow-up data at subsequent visits. Patients were followed at regular intervals dictated by their ongoing care at each local facility. More specifically, patients on ART were followed every one to three months, and those not on ART were followed every six months, unless there was a clinical event for which they needed to return to the clinic for evaluation and/or care. A facility doctor or nurse attended all patients. The same data collection forms were used at participating facilities in Burundi, Cameroon and DRC to collect data on socio-demographics, anthropometrics, risk behaviours, medical diagnoses (co-morbidities), laboratory values (CD4 counts, viral load, etc.), medications (antiretroviral (ARV), cotrimoxazole prophylaxis, TB prophylaxis and treatment) and dates of initiation, referrals and outcomes such as vital status and loss to follow-up. Data were abstracted from the existing electronic database at the participating sites in Rwanda and harmonized with the IeDEA-CA database. Data analysis relied predominantly upon descriptive methods and summary estimates. To enable comparisons between male and female participants, sex-stratified patient characteristics are also presented. To facilitate interpretation of these differences, p values derived from tests of comparison of the stratified estimates (x 2 test for categorical variables; Student's t or median tests for continuous variables) are presented. The statistical program Stata 12.1 (StataCorp LP, College Station, TX) was used for all analyses.
Human rights protection
The IeDEA-CA region research project was reviewed by the Institutional Review Board (IRB) at the Kinshasa School of Public Health in DRC, the national ethics committees in Burundi and Cameroon and the data coordinating centre IRB at RTI International. IRB approval was also obtained from the Rwanda National Ethics Committee to abstract data from already existing databases managed by the participating hospitals and that were made available to the International Center for AIDS Care and Treatment Programs (ICAP) at Columbia University and the Rwanda Women's InterAssociation Study (RWISA).
Results

Site and program characteristics
The 12 participating adult care sites were a combination of hospital and ambulatory care units of varying size/capacity, serving predominantly urban populations, and offering primary care in DRC, secondary care in Rwanda and tertiary care in Burundi and Cameroon (Table 2 ). All sites maintained on-site electronic databases for data storage and had a unique identifier for every patient. All sites recorded patients' education level and socio-economic status. While internet availability varied, regular transmissions ensured that the data coordinating centre database was up-to-date with the local databases at participating facilities. All sites documented drug stock-outs and reported some disruption of ARV medications during the last year, with duration that varied from one day in Rwanda to more than three weeks in DRC and Cameroon. All sites indicated that there were disruptions in prophylactic or opportunistic infection drug supply in the past year. Provision of routine HIV testing for patients' relatives, sex partners and household members was available in all sites, while some level of linkage to prevention of mother-to-child transmission (PMTCT) of HIV programs was also reported. All sites recorded history of PMTCT for female patients. With the exception of Burundi, the programs offered nutritional counselling to their patients and performed frequent anthropometric evaluations. A summary of program characteristics is presented by country in Table 2 .
Patient characteristics
The IeDEA-CA adult cohort characteristics are presented in Table 3 . DRC had 9871 patients, followed by Cameroon (n04922), Rwanda (n04583) and Burundi (n02223). Patients' mean (median) age ranged from 34 (33) years in Rwanda to 40 (40) in DRC. Marked differences were evident in disease status and mean CD4 counts between Rwanda and DRC, although these estimates were based on small sub-sets of patients that had CD4 values available. In DRC and Cameroon, two-thirds of patients were in WHO clinical Stage III or IV at enrolment into the IeDEA-CA database and virtually all (97%) of the 3224 patients with clinical stage information available in the Rwandan sites were in Stage I or II. One-third of participants in the Rwanda site had missing clinical stage information, whereas very few of the participants at the sites in the other three countries had missing clinical stage. More than half of the patients at the sites in DRC and Rwanda and 80% of the patients at the Burundi sites entered HIV care through VCT. About two-thirds of patients enrolled in each country were women though very few entered HIV care through PMTCT services in Burundi (3%), Cameroon (4%) and DRC (0.6%). About one-quarter of the patients in Rwanda entered HIV care through PMTCT.
With regard to differences between male and female participants, women were consistently younger (four to eight years mean difference) than men, in all country programs. Significantly higher proportions of men were married (i.e. 64% vs. 32% in DRC), while higher proportions of women were widowed (i.e. 31% vs. 11% in DRC). Women were enrolled into the IeDEA-CA database at an earlier disease stage than men, but this difference was most pronounced in the Cameroon sites. A larger proportion of men entered HIV care through VCT as compared to women. (Table 2 ). In the IeDEA participating sites in Burundi and Cameroon, approximately half of the patients who were enrolled in HIV care had initiated ART, when the IeDEA-CA baseline form was completed, whereas this proportion was one out of four in the IeDEA sites from DRC. In Rwanda, a small proportion of patients started ART at the enrolment visit, as this facility represents a point of entry to HIV care. Although the participating IeDEA-CA facilities in the other three countries also represent a point of entry into HIV care, many of these patients had already been receiving care at these facilities when the IeDEA-CA database was rolled out. The most common treatment regimen was d4T-30'3TC' NVP (stavudine/lamivudine/nevirapine (64%), followed by AZT'3TC'NVP (zidovudine/lamivudine/nevirapine (19%). Approximately one-third of patients had a drug substitution in Cameroon, whereas this proportion was smaller in Burundi (25%) and in DRC (15%). Four percent of patients underwent a change from first to second line regimens in Cameroon and Burundi, and less than 1% in DRC.
Discussion
The unique challenges of HIV care in sub-Saharan Africa require a ''systems approach'' based on operational research and a solid evidence-base [30, 31] . Gaining a pragmatic and comprehensive understanding of the current HIV care characteristics in the region is a pre-requisite for any intervention or ''fine-turning'' of current practices, reallocation of resources or other programmatic changes. The data presented here provide insights into HIV care within the Central Africa region and can set the stage for additional hypothesis-generating research and subsequent longitudinal investigations. It is imperative, however, that these observations are considered in the context of regional and countrylevel framing factors, to gain understanding into possible program-implementation gaps and differences [32] .
Between-country and -site differences: structural barriers to ART Country-level differences that frame HIV care are evident in the domains of urban/rural population ratio (e.g. Burundi: 11% vs. Cameroon: 56%), the estimated prevalence of HIV infection (DRC: 1.2Á1.5% vs. Cameroon: 5.1%) and the proportion of eligible adults receiving ART (approximately 20% for all countries except Rwanda: 71%) [26Á29]. Serious challenges have been reported in the implementation phase of ART programs in the region, and among those are important structural, health system, social and behavioural barriers to ART initiation and adherence [33, 34] . According to recent reports, the availability and adequacy of human resources in the health sector has been a major ART implementation impediment in Burundi [35] , whereas decentralization, HIV testing and referrals, and ARV supply have been additional structural barriers in Cameroon [36Á38]. Conversely, Rwanda has often been regarded as an example of successful build-up of health system infrastructures and decentralization of services across the country [39] . Studies based on quantitative [40] and qualitative [41, 42] methodology have provided valuable insights into the multilevel factors affecting patients' access to, initiation, and adherence to ART in the region. ''Common themes'' include patients' difficulty accessing HIV care sites due to distance, work and long waiting lines [41, 43, 44] , health personnel number and training inadequacies [45] , infrastructure insufficiencies [46] , poverty [47] , migration [48] and others. These factors (e.g. distance to the clinic) are important parameters when one considers the catchment population of the participating facilities, which served exclusively urban populations in Rwanda and DRC (with the exception of one site) and both urban and rural in Burundi and Cameroon. They also need to be taken into consideration when comparing the demographic and clinical profile of each country's cohort (i.e. compared to patients in the DRC sites, those followed in the Rwandan facilities had a seven-year younger median age and most were in WHO Stage I vs. III in DRC). Noteworthy, the large differences that were observed in ART initiation status and CD4 counts were affected by country characteristics, but also by each site's reference population (rural/urban), entry to HIV care and more.
Noteworthy, all sites used the then-current WHO criteria for ART initiation and treatment was offered free of charge to patients. Of course, entry to HIV care is of paramount importance, as recent findings among HIV-infected patients in sub-Saharan Africa [49] indicate that much of the excess mortality experienced among seropositive patients might be prevented by more timely initiation of ART.
Rwanda is the only country where participating IeDEA sites reported no ARV drug stock-outs and supply interruptions in the past year. This is an important finding, as hospital pharmacy ARV shortage was identified as a significant predictor of ART non-adherence among a sample of Cameroonian patients, in Yaoundé [40]. As mentioned above, patients enrolled in Rwanda were younger, tended to be enrolled into care at WHO clinical Stage I or II and had, acknowledging the missing data issue, higher CD4 counts. This observation, although limited by the non-representativeness of the study sample, is consistent with the high ART-enrolment proportion in Rwanda Á a PEPFAR-focus country, and the only focus country among our Central Africa cohort. Rwanda is one of eight low-and middle-income countries (and one of only two in Africa) that had achieved universal access to ART by December 2009 [50] . In 2008, PEPFAR was re-authorized with funds of nearly $50 billion and included a focus on strengthening existing health systems [20, 51] .
By-sex differences
Because sex-related disparities in HIV care are commonly reported [52, 53] , the presentation of sex-stratified patient characteristics of the IeDEA-CA clinical cohort is of interest. For example, recent data among HIV-infected individuals under care showed that women may experience higher mortality than men, even after controlling for HAART utilization [54] . In the current study, a larger proportion of men presented with Stage IV disease in sites in Cameroon and Burundi and had lower CD4 counts in all sites, which is consistent with other recent findings [55] . This, along with the observed demographic differences (men were older and more likely to be married), can be attributed to men's delay in seeking HIV care. Similarly, men's higher access via VCT may be due to their experience of disease symptoms, or selfdefinition as being at risk for HIV infection. More research is required to disentangle the contribution of social, cultural, behavioural, or biological and immunological factors [56Á59] to these by-sex differences.
Strengths and limitations
The main strength of the IeDEA-CA is the cohort's large number of seropositive individuals for whom socio-demographic and anthropometric data, clinical values, co-morbid conditions and treatment status were available. Moreover, the participating facilities benefited from the harmonization efforts in data collection, the quality assurance procedures and the improved data collection and management. As an example, many of the participating sites in Burundi, Cameroon and DRC began to use the IeDEA-CA data collection forms as the medical charts for patient care and the accompanying database as the electronic medical record system [60] . A reporting tool, available to each facility completing the IeDEA-CA forms, enabled physicians to produce reports by key variables (i.e. gender and ARV regimens) which were useful for clinic management, fulfilling reporting requirements for funding agencies and producing enrolment graphs for presentations and other advocacy activities. A listing of study ID numbers can be produced for patients that have not returned to clinic for scheduled appointments assisting clinic staff with lost to follow-up tracking. Prior to the IeDEA-CA database and accompanying reporting tool, many physicians and staff at the participating health facilities in Cameroon, Burundi and DRC were spending large amounts of time tallying these reports manually, which took away from patient care. However, patient management issues such as loss to follow-up remain a priority area for improvement.
While the IeDEA-CA adult HIV clinical care characteristics presented in this article reflect the participating facilities' characteristics and patients' profile, these data are neither nationally representative nor derived from randomly selected HIV care facilities; therefore, they lack the external validity that would permit between-country comparisons and inferences. Data completeness is another major limitation. For example, there were considerable proportions of missing information for marital status in DRC and Rwanda. Moreover, we have substantial proportions of missing information on patients' clinical stage, mainly in Rwanda, and CD4 counts, mainly in DRC, but also in Burundi and Rwanda. The extent of missing data is a reflection of systematic between-site differences, including enrolled patients' characteristics and stage of disease/treatment; however, disentangling these influences is not possible from these data. Additionally, the cohort faces the threats that all open clinical cohorts encounter, in terms of patient retention. The problem of substantial number of patients on ART being lost to follow-up in resource-limited settings has been well-documented, and measures to maximize ART program retention are warranted [61] . All participating IeDEA-CA sites had protocols for contacting and documenting the outcomes of those lost to follow-up.
Although, according to data of the last decade, small proportions of HIV-infected individuals actually received treatment in the Central Africa region, ranging from 2% to 26%, the more than 20,000 HIV-positive individuals that are followed in IeDEA-CA network facilities represent a considerable cohort. Nevertheless, more efforts are needed in the region to step-up efforts to provide treatment to all individuals that are in need of it.
Conclusions
The information presented in this paper outlines and provides insight into the program, site and patient characteristics with regard to HIV adult clinical care in selected facilities in Burundi, Cameroon, DRC and Rwanda. This robust cohort of more than 22,000 seropositive individuals demonstrates the feasibility of establishing large clinical cohorts of HIV-positive individuals in a relatively short amount of time in spite of challenges experienced by clinics in resourcelimited settings such as those in this region. Within its limitations, the IeDEA-CA network provides a unique framework for data collection harmonization and quality assurance, while offering a plethora of research opportunities that facilitate collaborative initiatives in the region. It is envisioned that the development of future research initiatives and additional program activities will enhance adult care HIV treatment in Central Africa and beyond.
